Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Cook

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Cell Cycle (Georgetown, Tex.)|March 10, 2016
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferationPamela A Lochhead, Jonathan Clark, Lan-Zhen Wang, et al.
Science Signaling|March 31, 2011
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cellsAnnette S Little, Kathryn Balmanno, Matthew J Sale, et al.
Bioconjugate Chemistry|April 29, 2017
Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent ProbeJames Sipthorp, Honorine Lebraud, Rebecca Gilley, et al.
Developmental Cell|January 27, 2016
Maternal DNA Methylation Regulates Early Trophoblast DevelopmentMiguel R Branco, Michelle King, Vicente Perez-Garcia, et al.
EMBO Molecular Medicine|October 14, 2010
V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4aLinda A S Carragher, Kimberley R Snell, Susan M Giblett, et al.
Cancer Research|January 7, 2006
Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and AktAndrew Sunters, Patricia A Madureira, Karen M Pomeranz, et al.
Nature Communications|March 15, 2020
Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitorsPamela A Lochhead, Julie A Tucker, Natalie J Tatum, et al.
Heliyon|January 4, 2019
Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERKFiona Hey, Catherine Andreadi, Catherine Noble, et al.
Cell Stem Cell|July 16, 2013
FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotencyGabriella Ficz, Timothy A Hore, Fátima Santos, et al.
Cellular and Molecular Life Sciences : CMLS|September 9, 2015
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndromeAnne L Ashford, Tom P J Dunkley, Mark Cockerill, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Cell Cycle (Georgetown, Tex.)|March 10, 2016
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferationPamela A Lochhead, Jonathan Clark, Lan-Zhen Wang, et al.
Science Signaling|March 31, 2011
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cellsAnnette S Little, Kathryn Balmanno, Matthew J Sale, et al.
Bioconjugate Chemistry|April 29, 2017
Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent ProbeJames Sipthorp, Honorine Lebraud, Rebecca Gilley, et al.
Developmental Cell|January 27, 2016
Maternal DNA Methylation Regulates Early Trophoblast DevelopmentMiguel R Branco, Michelle King, Vicente Perez-Garcia, et al.
EMBO Molecular Medicine|October 14, 2010
V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4aLinda A S Carragher, Kimberley R Snell, Susan M Giblett, et al.
Cancer Research|January 7, 2006
Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and AktAndrew Sunters, Patricia A Madureira, Karen M Pomeranz, et al.
Nature Communications|March 15, 2020
Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitorsPamela A Lochhead, Julie A Tucker, Natalie J Tatum, et al.
Heliyon|January 4, 2019
Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERKFiona Hey, Catherine Andreadi, Catherine Noble, et al.
Cell Stem Cell|July 16, 2013
FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotencyGabriella Ficz, Timothy A Hore, Fátima Santos, et al.
Cellular and Molecular Life Sciences : CMLS|September 9, 2015
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndromeAnne L Ashford, Tom P J Dunkley, Mark Cockerill, et al.
Pageof 10